These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32729905)

  • 1. Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy-a prospective multi-centre pilot study1.
    Bühler S; Jaeger VK; Eperon G; Furrer H; Fux CA; Jansen S; Neumayr A; Rochat L; Schmid S; Schmidt-Chanasit J; Staehelin C; de Visser AW; Visser LG; Niedrig M; Hatz C
    J Travel Med; 2020 Sep; 27(6):. PubMed ID: 32729905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of live vaccines on immunosuppressive or immunomodulatory therapy-a retrospective study in three Swiss Travel Clinics.
    Huber F; Ehrensperger B; Hatz C; Chappuis F; Bühler S; Eperon G
    J Travel Med; 2018 Jan; 25(1):. PubMed ID: 29394383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases.
    Tonacio AC; do Nascimento Pedrosa T; Borba EF; Aikawa NE; Pasoto SG; Filho JCRF; Sampaio Barros MM; Leon EP; Lombardi SCFS; Junior AM; Azevedo AS; Schwarcz WD; Fuller R; Yuki EFN; Ugolini Lopes MR; Rodrigues Pereira RM; Sampaio Barros PD; de Andrade DCO; de Medeiros-Ribeiro AC; de Moraes JCB; Shinjo SK; Miossi R; da Silva Duarte AJ; Lopes MH; Kallás EG; Almeida da Silva CA; Bonfá E
    PLoS Negl Trop Dis; 2021 Nov; 15(11):e0010002. PubMed ID: 34843469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period.
    Tanizaki R; Ujiie M; Hori N; Kanagawa S; Kutsuna S; Takeshita N; Hayakawa K; Kato Y; Ohmagari N
    J Travel Med; 2016 Mar; 23(3):. PubMed ID: 27021495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals.
    Burkhard J; Ciurea A; Gabay C; Hasler P; Müller R; Niedrig M; Fehr J; Villiger P; Visser LG; de Visser AW; Walker UA; Hatz C; Bühler S
    Vaccine; 2020 Apr; 38(19):3610-3617. PubMed ID: 31911033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid therapy: an observational cohort study.
    Kernéis S; Launay O; Ancelle T; Iordache L; Naneix-Laroche V; Méchaï F; Fehr T; Leroy JP; Issartel B; Dunand J; van der Vliet D; Wyplosz B; Consigny PH; Hanslik T
    Arthritis Care Res (Hoboken); 2013 Sep; 65(9):1522-8. PubMed ID: 23554297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yellow Fever Vaccination of a Primary Vaccinee During Adalimumab Therapy.
    Nash ER; Brand M; Chalkias S
    J Travel Med; 2015; 22(4):279-81. PubMed ID: 25922988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unpredictable checks of yellow fever vaccination certificates upon arrival in Tanzania.
    Schönenberger S; Hatz C; Bühler S
    J Travel Med; 2016 May; 23(5):. PubMed ID: 27296582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.
    Lindsey NP; Horiuchi KA; Fulton C; Panella AJ; Kosoy OI; Velez JO; Krow-Lucal ER; Fischer M; Staples JE
    J Travel Med; 2018 Jan; 25(1):. PubMed ID: 30346562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Staples JE; Gershman M; Fischer M;
    MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients.
    Colin de Verdiere N; Durier C; Samri A; Meiffredy V; Launay O; Matheron S; Mercier-Delarue S; Even S; Aboulker JP; Molina JM; Autran B; Simon F;
    AIDS; 2018 Oct; 32(16):2291-2299. PubMed ID: 30096071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.
    Valim V; Machado KLLL; Miyamoto ST; Pinto AD; Rocha PCM; Serrano EV; Dinis VG; Gouvêa SA; Dias JGF; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; da Costa-Rocha IA; de Lima SMB; Miranda EH; Trindade GF; Maia MLS; Gavi MBRO; da Silva LB; Duque RH; Gianordoli APE; Casagrande TZ; Oliveira KG; Moura BCDM; Nicole-Batista F; Rodrigues LC; Clemente TB; Magalhães ES; Bissoli MF; Gouvea MDPG; Pinto-Neto LFDS; Costa CZ; Giovelli RA; Brandão LR; Polito ETL; Koehlert IO; Borjaille BP; Pereira DB; Dias LH; Merlo DL; Genelhu LFF; Pretti FZ; Giacomin MDS; Burian APN; Fantinato FFST; Pileggi GS; da Mota LMH; Martins-Filho OA
    Front Immunol; 2020; 11():1382. PubMed ID: 32765496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yellow fever vaccine: past, present and future.
    Roukens AH; Visser LG
    Expert Opin Biol Ther; 2008 Nov; 8(11):1787-95. PubMed ID: 18847312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transmission of yellow fever vaccine virus from breast feeding mothers to their infants: reporting of yellow fever virus (YFV) RNA detection in milk specimens.
    Hassan T; Bashir RA; Abdelrahman DN; Madni H; M El Hussein AR; Elkidir IM; Enan KA
    F1000Res; 2022; 11():76. PubMed ID: 38106444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antibody responses in Japanese volunteers after immunization with yellow fever vaccine].
    Taga K; Imura S; Hayashi A; Kamakura K; Hashimoto S; Takasaki T; Kurane I; Uchida Y
    Kansenshogaku Zasshi; 2002 Sep; 76(9):738-46. PubMed ID: 12391677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of post-vaccination immunity against yellow fever in adults.
    Collaborative group for studies on yellow fever vaccines
    Vaccine; 2014 Sep; 32(39):4977-84. PubMed ID: 25090646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
    Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L;
    Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of fractional dosing of the 17DD Yellow Fever Vaccine among males and females: Experience of a community-based pharmacovigilance in Kinshasa, DR Congo.
    Nzolo D; Engo Biongo A; Kuemmerle A; Lusakibanza M; Lula Y; Nsengi N; Nsibu Ndosimao C; Tona Lutete G; Van Geertruyden JP
    Vaccine; 2018 Oct; 36(41):6170-6182. PubMed ID: 30190119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term immunity after a single yellow fever vaccination in travelers vaccinated at 60 years or older: A 10-year follow-up study.
    Rosenstein MD; de Visser AW; Visser LG; Roukens AHE
    J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34401911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.